*Dsam Partners Llp Maintains Stake in Anthem INC (ANTM)

It decreased its stake in Alteryx Inc by 86,187 shares to 169,405 shares, valued at $10.08 million in 2018Q4, according to the filing. Dsam Partners Llp …

Anthem, Inc. (NYSE:ANTM) Corporate Logo

In 2018Q4 SEC filling is reported Dsam Partners Llp’s holdings in Anthem Inc (ANTM) which was increased by 14.89%. The company’s stock popped up 0.44% while Dsam Partners Llp bought 16,611 shares. At the end of 2018Q4, the hedge fund held 128,158 shares of the health care company, valued at $33.66M, up from 111,547 at the end of the previous reported quarter. $74.63B is the MC of Anthem Inc. ANTM touched $290.1 during the last trading session after $0.6 change.Anthem, Inc. has volume of 1.06M shares. Since April 10, 2018 ANTM has risen 26.09% and is uptrending. The stock outperformed the S&P 500 by 21.72%.

About $480.85 million US Long portfolio Dsam Partners Llp operates. It decreased its stake in Alteryx Inc by 86,187 shares to 169,405 shares, valued at $10.08 million in 2018Q4, according to the filing. Dsam Partners Llp has cut its stake in Sabre Corp (NASDAQ:SABR) and also reduced its holding in Seaworld Entmt Inc (NYSE:SEAS) by 479,459 shares in the quarter, for a total of 441,123 shares.

For more Anthem, Inc. (NYSE:ANTM) news announced briefly go to: Investorplace.com, 247Wallst.com, Streetinsider.com, Seekingalpha.com or Gurufocus.com. The titles are as follows: “Best ETFs of 2019: The iShares U.S. Healthcare Providers ETF Is Suffering – Investorplace.com” announced on March 27, 2019, “Morgan Stanley Picks 30 Stocks for 2021 – 24/7 Wall St.” on March 15, 2019, “Piper Jaffray Sees 5 Overlooked Opportunities In LTSS (CNC ANTM UNH WCG MOH) – StreetInsider.com” with a publish date: April 09, 2019, “DOJ moves to strike down entire ACA – Seeking Alpha” and the last “Insurance Companies Benefit the Most From Rising Insulin Prices – GuruFocus.com” with publication date: March 27, 2019.

Anthem, Inc. (NYSE:ANTM) Ratings Coverage

In total 11 analysts cover Anthem (NYSE:ANTM). “Buy” rating has 10, “Sell” are 0, while 1 are “Hold”. (NYSE:ANTM) has 91% bullish analysts. With $391 highest and $292 lowest PT, Anthem has $350.33 average PT or 20.76% above the current ($290.1) price. 18 are the (NYSE:ANTM)’s ratings reports on 10 Apr 2019 according to StockzIntelligence Inc. On Thursday, November 1 the firm earned “Overweight” rating by Barclays Capital. In Thursday, January 3 report Evercore upgraded the stock to “Outperform” rating. On Thursday, March 7 Cantor Fitzgerald maintained Anthem, Inc. (NYSE:ANTM) rating. Cantor Fitzgerald has “Buy” rating and $360 target. On Thursday, January 31 Morgan Stanley maintained Anthem, Inc. (NYSE:ANTM) with “Overweight” rating. On Monday, December 3 the stock has “Buy” rating by Jefferies. In Wednesday, March 6 report Stephens maintained it with “Buy” rating and $350 target. In Friday, March 8 report BMO Capital Markets maintained the stock with “Buy” rating. On Friday, March 8 the stock of Anthem, Inc. (NYSE:ANTM) earned “Outperform” rating by Credit Suisse. On Friday, March 8 the stock of Anthem, Inc. (NYSE:ANTM) has “Buy” rating given by Barclays Capital. On Tuesday, December 4 Cantor Fitzgerald maintained Anthem, Inc. (NYSE:ANTM) rating. Cantor Fitzgerald has “Overweight” rating and $330 target.

Anthem, Inc. (NYSE:ANTM) Analyst Ratings Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Related Posts:

  • No Related Posts

Anthem Unit Looks To End 401(k) Plan Suit With $24M Deal

… offering the money market fund and allowing the Vanguard Group Inc., the plan’s record-keeper, to rack up excessive fees through revenue sharing …

By Danielle Nichole Smith

Law360 (April 8, 2019, 6:36 PM EDT) — An Anthem subsidiary has agreed to pay nearly $23.7 million to settle allegations that it mismanaged its multibillion-dollar 401(k) plan by letting participants pay excessive fees and invest in a poorly…

Related Posts:

  • No Related Posts

As Anthem INC (ANTM) Shares Rose, Shareholder Dsam Partners Llp Increased Stake by $4.35 …

Dsam Partners Llp has cut its stake in Alteryx Inc and also reduced its holding in Amazon Com Inc (NASDAQ:AMZN) by 7,126 shares in the quarter, …

Anthem, Inc. (NYSE:ANTM) Corporate Logo

Dsam Partners Llp’s holdings in Anthem Inc (ANTM) is rose by 14.89% based on its latest 2018Q4 regulatory filing with the SEC. By buying 16,611 shares Dsam Partners Llp made the stock popped up with 0.44%. The health care company reported $33.66M value for the 2018Q4. Now the hedge fund is holding 128,158 shares, compared to the 111,547 from the previous quarter. $75.46 billion is Anthem Inc’s market cap. Ticker’s shares touched $293.31 during the last trading session after 0.72% change.Anthem, Inc. has volume of 1.07 million shares. Since April 7, 2018 ANTM has risen 26.09% and is uptrending. ANTM outperformed by 21.72% the S&P 500.

A portfolio of $480.85 million is managed by Dsam Partners Llp. As it’s issued in SEC filling the stake in Marathon Pete Corp (NYSE:MPC) is reduced by 425,600 shares to 25,000 shares. They are valued at $1.48 million in 2018Q4. Dsam Partners Llp has cut its stake in Alteryx Inc and also reduced its holding in Amazon Com Inc (NASDAQ:AMZN) by 7,126 shares in the quarter, for a total of 11,873 shares.

For more Anthem, Inc. (NYSE:ANTM) news brought out briefly go to: Gurufocus.com, Investorplace.com, Seekingalpha.com, Fool.com or Benzinga.com. The titles are as follows: “Insurance Companies Benefit the Most From Rising Insulin Prices – GuruFocus.com” brought out on March 27, 2019, “Best ETFs of 2019: The iShares U.S. Healthcare Providers ETF Is Suffering – Investorplace.com” on March 27, 2019, “DOJ moves to strike down entire ACA – Seeking Alpha” with a publish date: March 26, 2019, “Top Health Insurance Stocks for 2019 – The motley Fool” and the last “Diplomat Pharmacy’s Valuation Presents Value To A Strategic Buyer, Raymond James Says In Upgrade (NYSE:DPLO) – Benzinga” with publication date: March 21, 2019.

Anthem, Inc. (NYSE:ANTM) Ratings Coverage

In total 11 analysts cover Anthem (NYSE:ANTM). “Buy” rating has 10, “Sell” are 0, while 1 are “Hold”. 91% are bullish. 18 are the (NYSE:ANTM)’s analyst reports since November 1, 2018 according to StockzIntelligence Inc. On Thursday, January 31 the stock of Anthem, Inc. (NYSE:ANTM) earned “Overweight” rating by Morgan Stanley. On Thursday, February 21 the firm has “Buy” rating by Morgan Stanley given. On Thursday, November 1 Barclays Capital maintained Anthem, Inc. (NYSE:ANTM) rating. Barclays Capital has “Overweight” rating and $300 target. On Friday, March 8 Cowen & Co maintained the shares of ANTM in report with “Buy” rating. The company rating was maintained by BMO Capital Markets on Thursday, November 1. The company rating was maintained by Jefferies on Monday, December 3. On Tuesday, November 6 the stock has “Neutral” rating by Citigroup. On Tuesday, December 4 Cantor Fitzgerald maintained Anthem, Inc. (NYSE:ANTM) with “Overweight” rating. The company rating was maintained by Credit Suisse on Friday, March 8. The stock rating was maintained by Stephens with “Buy” on Wednesday, March 6.

Anthem, Inc. (NYSE:ANTM) Analyst Ratings Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Related Posts:

  • No Related Posts

*Anthem INC (ANTM) Stake Maintained by Dsam Partners Llp

It manages about $480.85M US Long portfolio. For a total of 169,405 shares it reduced its holding in Alteryx Inc by 86,187 shares in the quarter, and …

Anthem, Inc. (NYSE:ANTM) Corporate Logo

Dsam Partners Llp upped its stake by 14.89% in Anthem Inc (ANTM), according to 2018Q4 SEC filling. The company’s stock rose 0.44% with the market as Dsam Partners Llp bought 16,611 shares. The health care company reported $33.66 million value for the 2018Q4. Now the hedge fund is holding 128,158 shares, compared to the 111,547 from the previous quarter. Anthem Inc has $75.46B market cap. ANTM is hitting $293.31 during the last trading session, after increased 0.72%.Anthem, Inc. has volume of 1.07 million shares. Since April 7, 2018 ANTM has risen 26.09% and is uptrending. The stock outperformed the S&P 500 by 21.72%.

The Dsam Partners Llp’s stake in Netflix Inc (NASDAQ:NFLX) was reduced by 23,407 shares to 19,020 shares valued at $5.09 million in 2018Q4, according to the filing. It manages about $480.85M US Long portfolio. For a total of 169,405 shares it reduced its holding in Alteryx Inc by 86,187 shares in the quarter, and has cut its stake in Amazon Com Inc (NASDAQ:AMZN).

For more Anthem, Inc. (NYSE:ANTM) news published briefly go to: Globenewswire.com, Gurufocus.com, 247Wallst.com, Seekingalpha.com or Investorplace.com. The titles are as follows: “Investor Expectations to Drive Momentum within Amphenol, Motorola Solutions, Interpublic Group of Companies, Anthem, Boingo Wireless, and Littelfuse — Discovering Underlying Factors of Influence – GlobeNewswire” published on March 25, 2019, “Insurance Companies Benefit the Most From Rising Insulin Prices – GuruFocus.com” on March 27, 2019, “Morgan Stanley Picks 30 Stocks for 2021 – 24/7 Wall St.” with a publish date: March 15, 2019, “Trump: Obamacare replacement will come after election – Seeking Alpha” and the last “Wellcare Acquisition Brings More Managed Care to CNC Stock – Investorplace.com” with publication date: March 27, 2019.

Anthem, Inc. (NYSE:ANTM) Ratings Coverage

In total 11 analysts cover Anthem (NYSE:ANTM). “Buy” rating has 10, “Sell” are 0, while 1 are “Hold”. (NYSE:ANTM) has 91% bullish analysts. With $391 highest and $292 lowest PT, Anthem has $350.33 average PT or 19.44% above the current ($293.31) price. 18 are the (NYSE:ANTM)’s ratings reports on 7 Apr 2019 according to StockzIntelligence Inc. The company rating was maintained by Jefferies on Monday, December 3. On Tuesday, November 6 the rating was maintained by Citigroup with “Neutral”. The stock rating was maintained by Credit Suisse with “Outperform” on Friday, March 8. The company rating was maintained by Barclays Capital on Thursday, November 1. On Thursday, March 7 the rating was maintained by Cantor Fitzgerald with “Buy”. In Thursday, November 1 report Credit Suisse maintained it with “Outperform” rating and $330 target. On Friday, March 8 the company was maintained by Barclays Capital. In Thursday, January 3 report Evercore upgraded the stock to “Outperform” rating. On Tuesday, December 4 the firm has “Overweight” rating by Cantor Fitzgerald given. In Thursday, February 21 report Morgan Stanley maintained it with “Buy” rating and $391 target.

Anthem, Inc. (NYSE:ANTM) Analyst Ratings Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Related Posts:

  • No Related Posts

Adamis Pharmaceuticals (ADMP) Reaches $2.01 52-Week Low; Dsam Partners Llp Lifted Anthem …

Alteryx Inc was reduced too. More news for Anthem, Inc. (NYSE:ANTM) were recently published by: Benzinga.com, which released: “Diplomat …

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) Logo

The stock of Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) hit a new 52-week low and has $1.85 target or 8.00% below today’s $2.01 share price. The 7 months bearish chart indicates high risk for the $95.06 million company. The 1-year low was reported on Mar, 25 by Barchart.com. If the $1.85 price target is reached, the company will be worth $7.60 million less. The stock decreased 6.07% or $0.13 during the last trading session, reaching $2.01. About 504,243 shares traded or 20.45% up from the average. Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) has declined 19.12% since March 25, 2018 and is downtrending. It has underperformed by 23.49% the S&P500. Some Historical ADMP News: 06/03/2018 ADAMIS PHARMACEUTICALS PROVIDES UPDATE ON DATA PRESENTED AT THE AMERICAN ACADEMY OF ALLERGY, ASTHMA AND IMMUNOLOGY (AAAAI) JOINT CONGRESS WITH THE WORLD ALLERGY ORGANIZATION; 06/03/2018 – Adamis Pharmaceuticals Provides Update on Data Presented at the American Academy of Allergy, Asthma and lmmunology (AAAAI) Joint Congress With the World Allergy Organization; 15/03/2018 – Adamis Pharmaceuticals Discusses 2017 Highlights and Business Update; 06/03/2018 – Adamis Pharmaceuticals Provides Update on Data Presented at the American Academy of Allergy, Asthma and Immunology (AAAAI) Join; 22/04/2018 – DJ Adamis Pharmaceuticals Corporation, Inst Holders, 1Q 2018 (ADMP); 08/03/2018 – Adamis Pharmaceuticals Announces Publication of a New Human Factors Study Comparing Its Symjepi™ Epinephrine Prefilled Syring; 08/03/2018 – Adamis Pharmaceuticals Announces Publication of a New Human Factors Study Comparing Its Symjepi™ Epinephrine Prefilled Syringe to the Market Leading Product in the Annals of Allergy, Asthma and lmmunology

Dsam Partners Llp increased Anthem Inc (ANTM) stake by 14.89% reported in 2018Q4 SEC filing. Dsam Partners Llp acquired 16,611 shares as Anthem Inc (ANTM)’s stock rose 0.44%. The Dsam Partners Llp holds 128,158 shares with $33.66 million value, up from 111,547 last quarter. Anthem Inc now has $76.18B valuation. The stock decreased 1.79% or $5.39 during the last trading session, reaching $296.12. About 379,277 shares traded. Anthem, Inc. (NYSE:ANTM) has risen 26.09% since March 25, 2018 and is uptrending. It has outperformed by 21.72% the S&P500. Some Historical ANTM News: 23/05/2018 – ANTHEM SEES ACQUISITION BOOSTING EARNINGS IN 2019; 24/05/2018 – Trump Says NFL Owners’ Anthem Protest Ban Doesn’t Go Far Enough; 23/05/2018 – N.F.L. Teams Will Be Fined for Players’ Anthem Kneeling; 23/05/2018 – ABC6: #BREAKING: #NFL implements standing for Anthem policy, players have option of staying in locker room…; 09/03/2018 – Haeggquist & Eck Investigates Anthem Directors and Officers for Breach of Fiduciary Duty Regarding Failed CIGNA Merger; 25/04/2018 – Anthem 1Q EPS $4.99; 15/05/2018 – THIRD POINT BOOSTED DOV, ANTM, WP, FB, LEN IN 1Q: 13F; 01/05/2018 – FITCH AFFIRMS ANTHEM’S ‘A+’ IFS RATING; MAINTAINS NEGATIVE OUTL; 17/05/2018 – Diageo Launches New American Anthem Vodka; 26/04/2018 – ANTHEM INC ANTM.N : JP MORGAN RAISES TARGET PRICE TO $287 FROM $261

Dsam Partners Llp decreased Seaworld Entmt Inc (NYSE:SEAS) stake by 479,459 shares to 441,123 valued at $9.74 million in 2018Q4. It also reduced Diamondback Energy Inc (NASDAQ:FANG) stake by 10,000 shares and now owns 20,000 shares. Alteryx Inc was reduced too.

More news for Anthem, Inc. (NYSE:ANTM) were recently published by: Benzinga.com, which released: “Diplomat Pharmacy’s Valuation Presents Value To A Strategic Buyer, Raymond James Says In Upgrade (NYSE:DPLO) – Benzinga” on March 21, 2019. 247Wallst.com‘s article titled: “Morgan Stanley Picks 30 Stocks for 2021 – 24/7 Wall St.” and published on March 15, 2019 is yet another important article.

Among 11 analysts covering Anthem (NYSE:ANTM), 10 have Buy rating, 0 Sell and 1 Hold. Therefore 91% are positive. Anthem had 18 analyst reports since November 1, 2018 according to SRatingsIntel. Credit Suisse maintained it with “Outperform” rating and $368 target in Friday, March 8 report. Barclays Capital maintained Anthem, Inc. (NYSE:ANTM) on Friday, March 8 with “Buy” rating. The stock of Anthem, Inc. (NYSE:ANTM) has “Outperform” rating given on Thursday, November 1 by BMO Capital Markets. The rating was maintained by Cantor Fitzgerald on Tuesday, December 4 with “Overweight”. The stock of Anthem, Inc. (NYSE:ANTM) has “Buy” rating given on Thursday, February 21 by Morgan Stanley. The rating was maintained by Stephens with “Buy” on Wednesday, March 6. The company was maintained on Thursday, November 1 by Credit Suisse. The stock has “Neutral” rating by Citigroup on Tuesday, November 6. The rating was maintained by Cantor Fitzgerald on Thursday, March 7 with “Buy”. The rating was maintained by Jefferies with “Buy” on Monday, December 3.

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company has market cap of $95.06 million. The companyÂ’s specialty pharmaceutical product candidates comprise Epinephrine Injection pre-filled syringe for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products consisting of albuterol (APC-2000) and fluticasone (APC-4000) for the treatment of bronchospasm and asthma; and beclomethasone (APC-1000), a metered dose inhaler product for the asthma, as well as APC-1000 and APC-5000 for the treatment of asthma and chronic obstructive pulmonary disease. It currently has negative earnings. It also operates a 503B drug outsourcing facility that provides prescription compounded medications to patients, physician clinics, hospitals, surgery centers, and other clients in the United States.

Among 3 analysts covering Adamis Pharmaceuticals (NASDAQ:ADMP), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Adamis Pharmaceuticals had 5 analyst reports since November 12, 2018 according to SRatingsIntel. The stock of Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) has “Buy” rating given on Tuesday, March 19 by Maxim Group. The firm earned “Neutral” rating on Monday, November 12 by FBR Capital. The stock has “Hold” rating by FBR Capital on Monday, March 18. The company was maintained on Tuesday, March 19 by Raymond James.

More notable recent Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) news were published by: Seekingalpha.com which released: “Adamis Pharmaceuticals: Refused, Accepted, Missed, And Predictable – Seeking Alpha” on March 21, 2019, also Nasdaq.com with their article: “Adamis Pharmaceuticals (ADMP) May Report Negative Earnings: Know the Trend Ahead of Q4 Release – Nasdaq” published on March 14, 2019, Seekingalpha.com published: “Midday movers and shakers – Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) – Seeking Alpha” on March 05, 2019. More interesting news about Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) were released by: Globenewswire.com and their article: “Adamis Provides Regulatory Update on Sublingual Tadalafil – GlobeNewswire” published on February 26, 2019 as well as Nasdaq.com‘s news article titled: “Health Care Sector Update for 02/27/2019: SGYP, BHC, TNDM, ADMP, JNJ, PFE, ABT, MRK, AMGN – Nasdaq” with publication date: February 27, 2019.

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) Ratings Chart

Related Posts:

  • No Related Posts